NEW YORK (

TheStreet

) -- In case you missed them, here are the top 10 most popular articles and videos on TheStreet today.

Sign up for free email delivery of our daily Top 10.

Biotech Stock Mailbag: Vivus, Chelsea, BioCryst

Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

General Electric's 'Cash Gusher' Will Lift Shares: Analyst

Dan Freed

The company's financial arm could pay $27 billion in dividends.

The 5 Dumbest Things on Wall Street: Feb. 17

Gregg Greenberg

Apple's China Troubles; MSG's Lin-sanity; Avon Gets Dinged; Energy Conversion Convulsion; Yahoo! Channels Charlie.

Bank Stock Rally's Biggest Enemy

Antoine Gara

Watch for a bank ratings cut to damper 2012 share gains of the largest U.S. banks.

The Next Big Thing in Biotech: Vivus, Chelsea

Adam Feuerstein

Senior columnist Adam Feuerstein explains why Vivus and Chelsea Therapeutics are the next big things in biotech.

Gilead Suffers First Hep C Drug Setback

Adam Feuerstein

Gilead's GS-7977 fails to cure hard-to-treat hepatitis C patients, showing the wonder drug has flaws.

Stocks Mixed as Investors Eye Greek Rescue Package

Andrea Tse

U.S. stocks were mixed Friday as investors digested greater confidence about a Greek bailout and varied national inflation reads.

Can Apple Investors Sue For a Dividend?

Chris Ciaccia

Apple had close to $100 billion in cash on its books at the end of the first quarter. Do investors have a legal right to it?

15 Hot, Highly Rated Technology Stocks of 2012 (Update 1)

Frank Byrt

These are proven gainers with a measure of safety.

Wells Fargo Is a Less Risky Bank of America

Philip van Doorn

In contrast to Bank of America's recent downgrade parade, Sterne Agee analyst Todd Hagerman on Friday raised his earnings estimate and price target for Wells Fargo, saying investors could see "an upside earnings surprise in 2012."

This article was written by a staff member of TheStreet.